Literature DB >> 16536758

Endoglin (CD105) expression in human renal cell carcinoma.

Johanna Sandlund1, Ylva Hedberg, Anders Bergh, Kjell Grankvist, Börje Ljungberg, Torgny Rasmuson.   

Abstract

OBJECTIVE: To evaluate the prognostic potential of endoglin (CD105) expression in human renal cell carcinoma (RCC), as endoglin is a cell membrane glycoprotein expressed in tumour-associated vascular endothelium and a marker of angiogenesis; intratumoral microvessel density assessed by endoglin staining has prognostic significance in some neoplasms. PATIENTS AND METHODS: Tumour samples from 210 patients with RCC (168 conventional), diagnosed between 1982 and 1997, were assessed using the tissue microarray technique with immunohistochemical staining for endoglin. The expression of endoglin was related to clinical variables and survival.
RESULTS: Of the tumours, 75% expressed endoglin, and in conventional RCC the expression was inversely correlated to the Tumour-Node-Metastasis (TNM) stage (P = 0.008) and nuclear grade (P = 0.01). There was no correlation between endoglin expression and gender, age, tumour size or cell type. Patients with conventional RCC and high endoglin expression had a more favourable prognosis than those with tumours with lower expression (P = 0.04). A multivariate analysis of prognostic factors showed that TNM stage and nuclear grade were independent predictors of prognosis. Endoglin expression did not add further prognostic information.
CONCLUSION: These results indicate that endoglin expression is inversely related to stage and grade in RCC, and that it is associated with prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16536758     DOI: 10.1111/j.1464-410X.2006.06006.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

Review 1.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

2.  Lack of association of microvessel density with prognosis of renal cell carcinoma: evidence from meta-analysis.

Authors:  Bing Zhang; Hong Ji; Dongliang Yan; Shaoqing Liu; Benkang Shi
Journal:  Tumour Biol       Date:  2013-11-23

3.  Transforming Growth Factor-β and Endoglin Signaling Orchestrate Wound Healing.

Authors:  Manoj Valluru; Carolyn A Staton; Malcolm W R Reed; Nicola J Brown
Journal:  Front Physiol       Date:  2011-11-29       Impact factor: 4.566

4.  Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Authors:  Tanya B Dorff; Jeff A Longmate; Sumanta K Pal; Walter M Stadler; Mayer N Fishman; Ulka N Vaishampayan; Amol Rao; Jacek K Pinksi; James S Hu; David I Quinn; Primo N Lara
Journal:  Cancer       Date:  2017-08-22       Impact factor: 6.921

5.  Metastasis-Initiating Cells in Renal Cancer.

Authors:  Mohammed I Khan; Anna M Czarnecka; Renata Duchnowska; Wojciech Kukwa; Cezary Szczylik
Journal:  Curr Signal Transduct Ther       Date:  2014-12

Review 6.  Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells.

Authors:  Zhi-Xiang Yuan; Jingxin Mo; Guixian Zhao; Gang Shu; Hua-Lin Fu; Wei Zhao
Journal:  Front Pharmacol       Date:  2016-11-10       Impact factor: 5.810

7.  Functional significance of CD105-positive cells in papillary renal cell carcinoma.

Authors:  Damian Matak; Klaudia K Brodaczewska; Cezary Szczylik; Irena Koch; Adam Myszczyszyn; Monika Lipiec; Slawomir Lewicki; Lukasz Szymanski; Robert Zdanowski; Anna M Czarnecka
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

8.  Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.

Authors:  Bo Cheng; Guosheng Yang; Rui Jiang; Yong Cheng; Haifan Yang; Lijun Pei; Xiaofu Qiu
Journal:  Oncotarget       Date:  2016-10-04

Review 9.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

10.  Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma.

Authors:  A Saroufim; Y Messai; M Hasmim; N Rioux; R Iacovelli; G Verhoest; K Bensalah; J-J Patard; L Albiges; B Azzarone; B Escudier; S Chouaib
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.